CD68 and neoplasm: Further analysis of the distribution of Siglec-15+CD68+TAMs in PD-L1− patients showed that stromal Siglec-15+CD68+TAMs of Mφ-Siglec-15+PD-L1− patients were significantly more than those of Mφ-Siglec-15−PD-L1− patients (p = 0.002; Fig. 4G), suggesting that stromal Siglec-15+CD68+TAMs may inhibit the infiltration of CD8+T cells into the tumor.